SEL1L2

Across TCGA pan-cancer cohorts, SEL1L2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SEL1L2 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SEL1L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEL1L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LGG, and OV are the cancer types where SEL1L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.119	0.678	<.001	24	view →
LGG	OS	Median	All	0.132	0.830	<.001	12	view →
OV	DFS	Median	All	0.142	0.541	.002	12	view →
BRCA	OS	Median	All	0.164	0.581	<.001	12	view →
READ	DFS	Median	III,IV	0.438	0.774	.004	8	view →
UCEC	DFS	Median	All	0.968	0.828	.019	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	III,IV	0.230	0.657	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SEL1L2–HNSC (DFS)

Open the HNSC breakdown →